- Excise policy case: Delhi court defers order on Sisodia's bail plea amidst pending curative petition
- Surveillance tightened in Sandeshkhali to prevent recurrence of tension
- SC asks UP govt to frame policy for timely payment of advocates' fees
- I have played with him and I am really proud of him: AB de Villiers on Sarfaraz Khan
- West Bengal govt seeks urgent listing of its suit against CBI probes in post-poll violence cases
- Army rushes to aid 500 tourists stranded after sudden snowfall in Sikkim
- Indian Navy provides medical assistance to Iranian fishing vessel
- Freed from circus, elephant Suzy celebrates nine years of freedom
- Will not shrink from countering any threat that undermines collective well-being: Rajnath
- Court takes cognisance of ED charge sheets against suspended CBI judge Sudhir Parmar
Wipro partners with Transcell Oncologics to transform vaccine safety assessment
Bengaluru: Wipro Ltd has announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI). ...
Bengaluru: Wipro Ltd has announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).
This partnership combines Transcell's stem cell technology with the augmented intelligence capabilities of Wipro 'HOLMES' to "improve the safety" of global vaccine immunisation programmes, Wipro, an IT, consulting and business process services company, said.
"By applying AI to the vaccine development process, our solution is capable of predicting adverse neurovirulent impacts resulting from vaccinations," Bengaluru-headquartered Wipro said in a statement.
Currently, vaccine safety assessment often includes testing on animals to measure adverse impacts, it said. "Using Wipro 'HOLMES' instead, researchers and biopharmaceutical companies have a new and fully viable solution and alternative.
Wipro 'HOLMES'can also be integrated into any existing workflow, including quality control tests in vaccine production, batchwise release and other safety evaluation assays," the statement added.
This partnership will also expand the Wipro 'HOLMES' solutions available to life science companies. The solution applies AI for drug repurposing and Messenger Ribonucleic Acid (mRNA)based platform for bio-defence.
It enables the testing of new vaccines by applying augmented intelligence to stem cell research and measuring safety and potency, the statement said.
"This is the first in a series of next generation solutions that the partnership will offer to determine the safety and efficacy of a wide-range of products from vaccines to prescription medications, cosmetics and more," it was stated.